July 2018
April 2018
Effect of Filgotinib, a Selective JAK1 Inhibitor, with or without Methotrexate in Patients with Rheumatoid Arthritis: Patient-Reported Outcomes
Arthritis Res Ther 2018; 20(1):57 doi: 10.1186/s13075-018-1541-z
Keywords:
March 2018
Response to Baricitinib based on Prior Biologic Use in Patients with Refractory Arthritis
Rheumatology (Oxford) 2018 May; 57(5):900-908
Keywords:
February 2018
Professor Iain McInnes Reviews the Most Important Papers from 2017
Please click the links below to go to the CSF review of each paper.
Keywords:
October 2017
Transaminase Levels and Hepatic Events During Tocilizumab Treatment: Pooled Analysis of Long-Term Clinical Trial Safety Data in Rheumatoid Arthritis
Arthritis Rheumatol. 2017 Sep;69(9):1751-1761. doi: 10.1002/art.40176
Keywords:
September 2017
Safety and Efficacy of Baricitinib through 128 Weeks in an Open-label, Longterm Extension Study in Patients with Rheumatoid Arthritis
J Rheumatol. 2018 Jan;45(1):14-21. doi: 10.3899/jrheum.161161
Keywords:
March 2017
A Phase IIb Study of ABT-494, a Selective JAK-1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti–Tumor Necrosis Factor Therapy
Arthritis Rheumatol 2016;68:2867–77
Keywords:
Efficacy and Safety of ABT-494, a Selective JAK-1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate
Arthritis Rheumatol 2016;68:2857–66
Keywords:
February 2017
Peficitinib, a JAK Inhibitor, in Combination with Limited Conventional Synthetic DMARDs in the Treatment of Moderate-to-severe Rheumatoid Arthritis
Arthritis Rheumatol DOI 10.1002/art.40054. Accepted article.
Keywords:
January 2017
Effects of Baricitinib on Lipid, Apolipoprotein, and Lipoprotein Particle Profiles in a Phase 2b Study in Patients with Active Rheumatoid Arthritis
Arthritis Rheumatol 2017. DOI 10.1002/art.40036.